Core Viewpoint - aTyr Pharma, Inc. is facing intensified financial and legal pressures following disappointing third-quarter results and ongoing securities class action litigation [1][4]. Financial Performance - aTyr reported a GAAP EPS loss of -$0.26 for Q3, missing analyst estimates by $0.08 [2]. - Revenues for the quarter were $190,000, indicating a reliance on the clinical pipeline rather than commercial sales [2]. Clinical Developments - Management plans to meet with the U.S. FDA in Q1 2026 to discuss the Phase 3 EFZO-FIT study results and the future of efzofitimod in treating pulmonary sarcoidosis [3]. - The EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [5]. Legal Issues - aTyr is involved in securities class action litigation alleging that the company misled investors about efzofitimod's efficacy [4][6]. - The class period for the lawsuit has been expanded to include investors who acquired shares from November 7, 2024, to September 12, 2025 [6]. - The litigation claims that aTyr's positive statements about the drug concealed deficiencies in its performance and trial design [7]. Market Reaction - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock fell over 83% in one day, from $6.03 to $1.02 [5].

Accessibility StatementSkip Navigation SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The suits allege that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices. At the heart ...

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. due to alleged securities fraud that affected shareholders between November 7, 2024, and September 12, 2025 [2][3]. Company Details - The lawsuit claims that aTyr Pharma provided misleading positive statements about the efficacy of its drug Efzofitimod while concealing material adverse facts regarding its ability to allow patients to taper off steroid usage [3][4]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [4]. Stock Performance - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a significant decline of 83.2% in just one day [5]. Legal Action - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [6]. Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroids completely [5]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [6]. - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [6].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1]. Summary by Sections Allegations - The complaint alleges that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly its ability to allow patients to taper steroid usage completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [1]. Stock Price Impact - Following the announcement of the disappointing study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug efzofitimod, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about efzofitimod, particularly regarding its ability to allow patients to taper steroid usage [5]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [6]. - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [6]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [7]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding aTyr's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - The complaint alleges that defendants made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a stock price decline from $6.03 to $1.02, an 83.2% drop in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the drug Efzofitimod, which led to significant financial losses for investors [1][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1]. Allegations Against aTyr - The complaint alleges that aTyr and its executives made false and misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper off steroid usage completely [3]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant change in mean daily oral corticosteroid dose at week 48, with a reduction of only 2.79 mg for the drug compared to 3.52 mg for placebo [4]. Stock Performance Impact - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [4].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 7, 2024, and September 12, 2025 [1][2] - The lawsuit claims that aTyr provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr dropped significantly by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Class Action Details - Investors who suffered losses during the specified timeframe can request to be appointed as lead plaintiff by December 8, 2025 [3] - Participation in the class action does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit claims that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5]. Group 3: Next Steps for Investors - To join the class action, investors can visit the provided link or contact the law firm directly for more information [4][7]. - It is noted that no class has been certified yet, and investors are not represented unless they retain counsel [8].